HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The future of surfactant therapy for patients with acute lung injury - new requirements and new surfactants.

Abstract
New requirements must be considered when designing trials of new lung surfactants for patients with acute lung injury (ALI). Radiographic inclusion criteria must be carefully applied if they are to generate reproducible patient groups. Strategies for ventilation are now known to significantly affect outcome and also must be clearly defined and applied. Similar mortality rates in patients with different degrees of gas exchange and radiographic abnormalities suggest that prior clinical distinctions should be re-examined. Current trials of surfactant therapy for ALI are examining the efficacy of a natural surfactant, a surfactant containing recombinant SP-C and a surfactant based on an SP-B-like peptide.
AuthorsRoger G Spragg
JournalBiology of the neonate (Biol Neonate) Vol. 81 Suppl 1 Pg. 20-4 ( 2002) ISSN: 0006-3126 [Print] Switzerland
PMID12011562 (Publication Type: Journal Article, Review)
CopyrightCopyright 2002 S. Karger AG, Basel
Chemical References
  • Pulmonary Surfactants
Topics
  • Acute Disease
  • Animals
  • Animals, Newborn (physiology)
  • Drug Industry (trends)
  • Humans
  • Infant, Newborn
  • Infant, Newborn, Diseases (drug therapy)
  • Lung Diseases (drug therapy)
  • Neonatology (trends)
  • Pulmonary Surfactants (therapeutic use)
  • Respiratory Distress Syndrome, Newborn (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: